243 related articles for article (PubMed ID: 36273925)
21. Efficacy of hyperthermic intraperitoneal chemotherapy in patients with epithelial ovarian cancer: a meta-analysis.
Wu Q; Wu Q; Xu J; Cheng X; Wang X; Lu W; Li X
Int J Hyperthermia; 2019; 36(1):562-572. PubMed ID: 31137989
[No Abstract] [Full Text] [Related]
22. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
23. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
Eur J Cancer; 2020 Mar; 127():76-95. PubMed ID: 31986452
[TBL] [Abstract][Full Text] [Related]
24. Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.
Bouchard-Fortier G; Cusimano MC; Fazelzad R; Sajewycz K; Lu L; Espin-Garcia O; May T; Bouchard-Fortier A; Ferguson SE
Gynecol Oncol; 2020 Jul; 158(1):218-228. PubMed ID: 32387131
[TBL] [Abstract][Full Text] [Related]
25. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials.
Filis P; Mauri D; Markozannes G; Tolia M; Filis N; Tsilidis K
ESMO Open; 2022 Oct; 7(5):100586. PubMed ID: 36116421
[TBL] [Abstract][Full Text] [Related]
26. Developing a hyperthermic intraperitoneal chemotherapy (HIPEC) gynecologic oncology program: a Canadian experience.
Neveu J; Tremblay E; Mercier F; Garneau S; Cormier B
Int J Gynecol Cancer; 2023 Dec; 33(12):1957-1965. PubMed ID: 38011988
[TBL] [Abstract][Full Text] [Related]
27. Hyperthermic intraperitoneal chemotherapy in the treatment of recurrent ovarian cancer: When, and for whom?
Ayhan A; Akilli H; Abasiyanik MA; Taskiran C
J Surg Oncol; 2023 Mar; 127(3):457-464. PubMed ID: 36264620
[TBL] [Abstract][Full Text] [Related]
28. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
[TBL] [Abstract][Full Text] [Related]
29. Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: a retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer.
Marocco F; Vaira M; Milani A; Genta S; Maggiorotto F; Magistris A; Cinquegrana A; Robella M; De Simone M; Aglietta M; Ponzone R; Valabrega G
Eur J Gynaecol Oncol; 2016; 37(5):638-643. PubMed ID: 29787001
[TBL] [Abstract][Full Text] [Related]
30. Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer.
Brault C; Brind'Amour A; de Guerke L; Auclair MH; Sideris L; Dubé P; Soucisse M; Tremblay JF; Bernard L; Piedimonte S; Fortin S
Curr Oncol; 2023 Dec; 30(12):10272-10282. PubMed ID: 38132382
[TBL] [Abstract][Full Text] [Related]
31. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis.
Zhang G; Zhu Y; Liu C; Chao G; Cui R; Zhang Z
J Ovarian Res; 2019 Apr; 12(1):33. PubMed ID: 30995948
[TBL] [Abstract][Full Text] [Related]
32. An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer.
de Bree E; Michelakis D
Expert Opin Pharmacother; 2020 Aug; 21(12):1479-1492. PubMed ID: 32486865
[TBL] [Abstract][Full Text] [Related]
33. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.
Lim PQ; Han IH; Seow KM; Chen KH
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077477
[TBL] [Abstract][Full Text] [Related]
34. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Gelissen JH; Adjei NN; McNamara B; Mutlu L; Harold JA; Clark M; Altwerger G; Dottino PR; Huang GS; Santin AD; Azodi M; Ratner E; Schwartz PE; Andikyan V
Ann Surg Oncol; 2023 Sep; 30(9):5597-5609. PubMed ID: 37358686
[TBL] [Abstract][Full Text] [Related]
35. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.
Baiocchi G; Ferreira FO; Mantoan H; da Costa AA; Faloppa CC; Kumagai LY; de Mello CA; Takahashi RM; Nakagawa WT; Aguiar S; Lopes A
Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430
[TBL] [Abstract][Full Text] [Related]
36. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
[TBL] [Abstract][Full Text] [Related]
37. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.
Aronson SL; Lopez-Yurda M; Koole SN; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van Gent MDJM; Arts HJG; van Ham MAPC; van Dam PA; Vuylsteke P; Aalbers AGJ; Verwaal VJ; Van de Vijver KK; Aaronson NK; Sonke GS; van Driel WJ
Lancet Oncol; 2023 Oct; 24(10):1109-1118. PubMed ID: 37708912
[TBL] [Abstract][Full Text] [Related]
38. A phase 2 trial of short-course Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) at interval cytoreductive surgery (iCRS) for advanced ovarian cancer.
Batista TP; Carneiro VCG; Tancredi R; Badiglian Filho L; Rangel RLC; Lopes A; Sarmento BJQ; Leão CS
Rev Col Bras Cir; 2022; 49():e20223135. PubMed ID: 35239855
[TBL] [Abstract][Full Text] [Related]
39. Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review.
van Stein RM; Aalbers AGJ; Sonke GS; van Driel WJ
JAMA Oncol; 2021 Aug; 7(8):1231-1238. PubMed ID: 33956063
[TBL] [Abstract][Full Text] [Related]
40. The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer.
Bhatt A; Glehen O; Zivanovic O; Brennan D; Nadeau C; Van Driel W; Bakrin N
Ann Surg Oncol; 2023 Dec; 30(13):8115-8137. PubMed ID: 37561343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
